WikiDoc Resources for COVID-19-associated headache
Evidence Based Medicine
Guidelines / Policies / Govt
Patient Resources / Community
Healthcare Provider Resources
Continuing Medical Education (CME)
Experimental / Informatics
Synonyms and keywords:
The association between COVID-19 and headache was made in 2020. COVID-19 associated headache may be caused by the SARS-CoV-2 virus. There is no established system for the classification of COVID-19 associated headache. The exact pathogenesis of headache in COVID-19 patients is not fully understood. It is thought that headache is the result of cytokine release, direct invasion, metabolic disturbances, inflammation, dehydration, and hypoxia. COVID-19-associated headache must be differentiated from other diseases that cause headache, such as migraine, tension-type headache, cluster headache, seizure, meningitis, encephalitis, neurosyphilis, SAH, subdural hematoma, brain tumor, hypertensive encephalopathy, brain abscess, multiple sclerosis, hemorrhagic stroke, Wernickes encephalopathy, and drug toxicity. A positive history of fever and cough in addition to headache is suggestive of COVID-19-associated headache.
- The association between COVID-19 and headache was made in December, 2019 during the SARS-CoV-2 outbreak initiated in Wuhan, Hubei Province, China.
- There is no established system for the classification of COVID-19 associated headache.
- The exact pathogenesis of headache in COVID 19 patients is not fully understood.
- It is thought that headache is the result of:
- COVID-19 associated headache may be caused by SARS-CoV-2 virus.
Differentiating COVID-19-associated headache from other Diseases
- For further information about the differential diagnosis, click here.
- To view the differential diagnosis of COVID-19, click here.
Epidemiology and Demographics
Incidence / Prevalence
- WHO reported that more than 462,801 people have been infected worldwide, more than 380,723 of which are outside of China.
- The incidence/prevalence of COVID-19-associated headache is still unknown.
- Guan et al. recently reported 13 percent of COVID-19-associated headache among 1099 laboratory-confirmed cases.
- There is insufficient information regarding age-specific prevalence or incidence of COVID-19-associated headache.
- There is insufficient information regarding gender-specific prevalence or incidence of COVID-19-associated headache.
- There is insufficient information regarding race-specific prevalence or incidence of COVID-19-associated headache.
- There are no established risk factors for COVID-19-associated headache.
Natural History, Complications, and Prognosis
- At this point, the natural history of COVID-19-associated headache is unknown.
- Further studies are needed to better understand the COVID-19-associated headache.
- Patients with a history migraine may experience headache as their first symptom, and these patients experience more severe headache and are more disabled by the infection compared with age‐matched cohorts.
- Further studies are needed to better understand complications.
- Larger retrospective studies are needed for evaluating the experience of COVID‐19 in patients with a history of a primary headache disorder.
Diagnostic Study of Choice
- There are no established criteria for the diagnosis of COVID-19-associated headache.
History and Symptoms
- The hallmark of COVID-19-associated headache is headache.
- A positive history of fever and cough in addition to headache is suggestive of COVID-19-associated headache.
- Common symptoms of COVID-19-associated headache are:
Less Common Symptoms
- Less common symptoms of COVID-19-associated headache are:
- Patients with COVID-19-associated headache usually appear normal.
- Physical examination of patients with COVID-19-associated headache is usually remarkable for fever, cough, and malaise.
- Additional diagnostic tests like blood chemistry and urine analysis may be needed to rule out other medical conditions.
Echocardiography or Ultrasound
- There are no CT scan findings associated with COVID-19-associated headache.
- There are no MRI findings associated with COVID-19-associated headache.
Other Imaging Findings
- There are no other imaging findings associated with COVID-19-associated headache.
Other Diagnostic Studies
- There are no other diagnostic studies associated with COVID-19-associated headache.
- Medical therapy for COVID-assocaited-headache is still controversial.
- The use of NSAIDs, who received treatment early in the disease causes worsening of COVID-19 symptoms according to some anecdotal evidences.
- In March 11, 2020, Fang et al. reported the hypothesis that ibuprofen (40 mg/kg/dose) can increase the risk of developing severe and fatal COVID-19 since ibuprofen is known to upregulate ACE2 receptors.
- In March 23, 2020, US FDA announced that it is not aware of any evidence that NSAIDs such as ibuprofen could worsen COVID-19.
- The European Medicines Agency and World Health Organization (WHO) have not yet recommended that NSAIDs be avoided.
- Despite this recommendation, as a precautionary measure many providers are avoiding NSAIDs in patients with COVID-19.
- In practice, the decision to continue or stop NSAIDs in patients with COVID-19 is made in collaboration between the treating physician and the patient, after a brief discussion on the limited available evidence.
- More data are needed before broad recommendations are made.
- There are no established measures for the primary prevention of COVID-19 associated headache.
- There are no established measures for the secondary prevention of COVID-19-associated headache.
- Meng X, Deng Y, Dai Z, Meng Z (June 2020). "COVID-19 and anosmia: A review based on up-to-date knowledge". Am J Otolaryngol. 41 (5): 102581. doi:10.1016/j.amjoto.2020.102581. PMC 7265845 Check
|pmc=value (help). PMID 32563019 Check
- Baig, Abdul Mannan; Khaleeq, Areeba; Ali, Usman; Syeda, Hira (2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chemical Neuroscience. 11 (7): 995–998. doi:10.1021/acschemneuro.0c00122. ISSN 1948-7193.
- St-Jean JR, Jacomy H, Desforges M, Vabret A, Freymuth F, Talbot PJ (August 2004). "Human respiratory coronavirus OC43: genetic stability and neuroinvasion". J. Virol. 78 (16): 8824–34. doi:10.1128/JVI.78.16.8824-8834.2004. PMC 479063. PMID 15280490.
- Rossi, Andrea (2008). "Imaging of Acute Disseminated Encephalomyelitis". Neuroimaging Clinics of North America. 18 (1): 149–161. doi:10.1016/j.nic.2007.12.007. ISSN 1052-5149.
- St-Jean, Julien R.; Jacomy, Hélène; Desforges, Marc; Vabret, Astrid; Freymuth, François; Talbot, Pierre J. (2004). "Human Respiratory Coronavirus OC43: Genetic Stability and Neuroinvasion". Journal of Virology. 78 (16): 8824–8834. doi:10.1128/JVI.78.16.8824-8834.2004. ISSN 0022-538X.
- Tu H, Tu S, Gao S, Shao A, Sheng J (2020). "Current epidemiological and clinical features of COVID-19; a global perspective from China". J Infect. 81 (1): 1–9. doi:10.1016/j.jinf.2020.04.011. PMC 7166041 Check
|pmc=value (help). PMID 32315723 Check
- Zhang J, Xie B, Hashimoto K (2020). "Current status of potential therapeutic candidates for the COVID-19 crisis". Brain Behav Immun. 87: 59–73. doi:10.1016/j.bbi.2020.04.046. PMC 7175848 Check
|pmc=value (help). PMID 32334062 Check
- MaassenVanDenBrink A, de Vries T, Danser A (April 2020). "Headache medication and the COVID-19 pandemic". J Headache Pain. 21 (1): 38. doi:10.1186/s10194-020-01106-5. PMC 7183387 Check
|pmc=value (help). PMID 32334535 Check
|pmid=value (help). Vancouver style error: initials (help)
- Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8 (4):e21. DOI:10.1016/S2213-2600(20)30116-8 PMID: 32171062
- FitzGerald GA (2020) Misguided drug advice for COVID-19. Science 367 (6485):1434. DOI:10.1126/science.abb8034 PMID: 32198292